Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17396257 | 0.78 | NPC1 (0.47) | HDAC8MAOB | |
| SCHEMBL25384738 | 0.73 | HDAC1 (0.38) | HDAC8HDAC6MAOBKDM1AKCNH2 | |
| SCHEMBL17396232 | 0.73 | RAB9A (0.46) | MAOB | |
| SCHEMBL17780006 | 0.73 | KDM1A (0.58) | KDM1AKCNH2KDM1BIDO1 | |
| SCHEMBL17396337 | 0.71 | KDM1A (0.40) | HDAC8HDAC6HDAC3HDAC11KDM1A | |
| SCHEMBL6154851 | 0.69 | HDAC3 (0.51) | HDAC8HDAC6HDAC3HDAC11DEGS1 | |
| SCHEMBL17396076 | 0.68 | MAOB (0.55) | HDAC6MAOBKDM1AHDAC1KLKB1 | |
| SCHEMBL29074408 | 0.67 | HDAC3 (0.49) | HDAC8HDAC6HDAC3HDAC11DEGS1 | |
| SCHEMBL20596701 | 0.67 | KDM1A (0.55) | HDAC8HDAC6KDM1AKCNH2KDM1B | |
| SCHEMBL24670922 | 0.66 | TP53 (0.63) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3511319-B1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2023-05-03 | — | — | EP | disclosed |
| EP-3511319-B1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2023-05-03 | — | — | EP | disclosed |
| EP-3164380-B1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3164380-B1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3511319-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Celgene Quanticel Research, Inc. (US) | 2019-07-17 | — | — | EP | disclosed |
| EP-3511319-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Celgene Quanticel Research, Inc. (US) | 2019-07-17 | — | — | EP | disclosed |
| US-20190002456-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2019-01-03 | — | — | US | disclosed |
| US-20190002456-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2019-01-03 | — | — | US | disclosed |
| US-10100046-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| US-20180127408-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2018-05-10 | — | — | US | disclosed |
| US-20180127408-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2018-05-10 | — | — | US | disclosed |
| US-9902719-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-9902719-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-9902719-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-20170129882-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-05-11 | — | — | US | disclosed |
| US-20170129882-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-05-11 | — | — | US | disclosed |
| US-20170129882-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-05-11 | — | — | US | disclosed |
| EP-3164380-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Celgene Quanticel Research, Inc. (US) | 2017-05-10 | — | — | EP | disclosed |
| WO-2016003917-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Quanticel Pharmaceuticals, Inc. (US) | 2016-01-07 | — | — | WO | disclosed |
| WO-2016003917-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Quanticel Pharmaceuticals, Inc. (US) | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129882-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | HDAC8 139/4885HDAC6 306/4885HDAC3 123/4885 |
| US-20180127408-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | HDAC8 139/4885HDAC6 306/4885HDAC3 123/4885 |
| US-10100046-B2 | Inhibitors of lysine specific demethylase-1 | KDM1B, KDM1A, KDM3A | HDAC8 139/4885HDAC6 306/4885HDAC3 123/4885 |
| US-20190002456-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | HDAC8 139/4885HDAC6 306/4885HDAC3 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.